Partnering & innovation
Novo Nordisk Compound Sharing
Sharing our compounds with you
Driving innovation through sharing
Accelerate innovation
To accelerate innovation, we openly share novel peptide and protein analogues as well as antibodies for preclinical research.
Through this open innovation initiative, we offer easy and free access to selected high-quality and well-characterized compounds to curious and passionate scientists from around the world. We hope that sharing can advance the research of those who want to discover new mode of action and expand disease biology understanding, which can ultimately contribute to accelerating future breakthroughs for medical solutions.
The process and criteria are simple and transparent - we provide the compounds for free for you to validate your scientific hypothesis, you own the results and are encouraged to publish these. There is no reporting required but if you obtain exciting new results, you are welcome to get in touch for a discussion of the data and the possibilities for a future collaboration.
For COVID-19 related compounds, please contact Department Manager Theresa Bak-Thomsen, TBT@novonordisk.com.
The process
Through a few easy steps you can get access to our compounds
Available compounds
Explore and learn more about our compounds
Tine Glendorf and Lars Linderoth, scientists from the Novo Nordisk Compound Sharing team
Contact us
If you have questions or comments in relation to Compound Sharing do not hesitate to contact us. You are also welcome to take a look at the FAQs at the bottom of this page.
You can reach us at compoundsharing@novonordisk.com – we are looking forward to answering your questions.
FAQs
People often ask us
Careers in R&D
We are looking for scientific talent to join us. If you are interested in joining our research and development teams, explore your opportunities at our careers page.
Partnering opportunities
Interested in partnering with Novo Nordisk? We constantly seek innovative alliances with academic and healthcare institutions, as well as leading biotechnology and pharmaceutical companies.